Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.
Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.
Cancer Rep (Hoboken). 2020 Oct;3(5):e1282. doi: 10.1002/cnr2.1282. Epub 2020 Sep 7.
Therapy-related leukemia is a well-recognized clinical syndrome. Peptide receptor radionuclide therapy (PRRT) is a modern therapeutic approach using radionuclide combined with somatostatin analog peptide for inoperable or metastatic neuroendocrine tumors.
Hematologic toxicities including late-onset myeloid neoplasms have been reported after PRRT; however, therapy-related chronic myeloid leukemia (TR-CML) following PRRT is a relatively rare entity.
We present a 64-year-old male who received PRRT for pancreas neuroendocrine tumor and then developed TR-CML 60 months after the initiation of PRRT. The patient responded well to imatinib therapy.
Patients with TR-CML generally have similar tyrosine kinase inhibitor responses and outcomes when compared to de novo cases.
The physicians should be aware of the short- and long-term hematologic toxicities of PRRT including TR-CML, and careful monitoring is mandatory in this group of patients.
治疗相关性白血病是一种公认的临床综合征。肽受体放射性核素疗法（PRRT）是一种使用放射性核素与生长抑素类似肽结合治疗不可切除或转移性神经内分泌肿瘤的现代治疗方法。
PRRT 后可出现血液学毒性，包括迟发性髓系肿瘤；然而，PRRT 后治疗相关性慢性髓性白血病（TR-CML）较为少见。
我们报告了 1 例 64 岁男性，因胰腺神经内分泌肿瘤接受 PRRT 治疗，在 PRRT 开始后 60 个月发生 TR-CML。该患者对伊马替尼治疗反应良好。
与初发病例相比，TR-CML 患者通常对酪氨酸激酶抑制剂有相似的反应和结局。
医生应了解 PRRT 的短期和长期血液学毒性，包括 TR-CML，并对这组患者进行密切监测。
